Immuno-oncology
Jointly provided by UVA Health; ASCP and The Society for Black Pathologists, these Two 90-minute, previously recorded, credit-bearing tumor boards will feature a multidisciplinary panel of experts discussing complex patient cases in melanoma, NSCLC, bladder, and renal cell cancers, which are all candidates for combination immunotherapy and common in minority populations.
Throughout the virtual tumor boards, presenters will weave in health equity concepts to support equitable care for patients who can potentially benefit from immunotherapy therapies for a cancer diagnosis.
This online module is designed to help you increase your scientific knowledge around recent approvals of combination I-O therapies, emerging I-O biomarkers, and biomarker testing challenges. You will also learn techniques for overcoming common barriers and common myths and misconceptions related to biomarker testing.
Topics: immuno-oncology; I-O Biomarkers
This activity is funded by an independent educational grant from Bristol Myers Squibb.